Publication: A Poly (Lactic Co Glycolic) Acid Based Dry Powder Inhaler for the Treatment of Pulmonary Tuberculosis
No Thumbnail Available
Date
2017-11-13
Authors
Published Version
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Research Data
Abstract
The goal of this paper was to investigate the feasibility of a novel Poly (Lactic Co Glycolic) Acid (PLGA) based Dry Powder Inhaler in the treatment of pulmonary tuberculosis. First line TB drugs are highly effective in treating TB, but the lengthy treatment course and side effects associated with their use impacts negatively on treatment compliance. The advantages of using a Dry Powder Inhaler containing a fixed dose combination of first line antitubercular drugs in a PLGA carrier are investigated. Issues relating to the adequacy of current World Health Organization dosing recommendations are discussed and a set of clinical trials is proposed to assess the safety and efficacy of the Dry Powder Inhaler.
Description
Other Available Sources
Keywords
Biology, General
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service